AR 2015

Q1 Report 2016

Galapagos kick-starts 2016 with Q1 cash position of €988 M

Click here for the Q1 Report 2016Join our webcast 29 April 14.00 CET

Welcome to Galapagos

Galapagos seeks to develop a robust portfolio of clinical-stage breakthrough therapies that have the potential to revolutionize existing treatment paradigms. Our ambition is to become a leading global biotechnological company, focused on the development and commercialization of novel medicines that will improve people’s lives.

Learn more about Galapagos

Novel targets, better treatments

Watch our target discovery animation. 

Read more

Filgotnib

Global development filgotinib

Galapagos and Gilead have announced a global partnership to develop and commercialize filgotinib for the treatment of rheumatoid arthritis and other inflammatory diseases.

Read more